Non-invasive, immuno-dynamic, biomarkers positioned in cancer patient’s blood milieu with immuno-oncological applications are rare. We recently established a “first-in-class” serum functional immunodynamics status (sFIS) assay, wherein in vitro assessment of serum-induced myeloid NFkB and/or interferon (IFN) response-signaling can be performed to “mimic” in situ patient’s serum immune-biology. This modality has clear implications for anticipating patient prognosis and immunotherapy-relevant stratification.
CITATION STYLE
Sprooten, J., Coosemans, A., & Garg, A. D. (2022). A first-in-class, non-invasive, immunodynamic biomarker approach for precision immuno-oncology. OncoImmunology, 11(1). https://doi.org/10.1080/2162402X.2021.2024692
Mendeley helps you to discover research relevant for your work.